author-photo

Lajos Pusztai

University of Texas MD Anderson Cancer Center
Yale University
Yale Cancer Center

741

Papers

41395

Citations

Citation Trend

Filter By

Papers (741) Sort By

Journal Conference Others

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (1)
Quantitative Assessment of the Immune Microenvironment in African American Triple Negative Breast Cancer: A Case Control Study

2021
Show All
- Source
- Cite
- Save
Citations (0)
A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples.

2021 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A Network Propagation Approach to Prioritize Long Tail Genes in Cancer

2021 bioRxiv
Show All
- Source
- Cite
- Save
Citations (1)
Evidence of Accelerated Epigenetic Aging of Breast Tissues In Patients With Breast Cancer Is Driven By CpGs Associated With Polycomb Related Genes

2021
Show All
- Source
- Cite
- Save
Citations (0)
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

2021 Cancer Cell
Show All
- Source
- Cite
- Save
Citations (5)